Literature DB >> 35382519

Progressive multifocal leukoencephalopathy in a patient with systemic sclerosis treated with methotrexate: A case report and literature review.

Theodora Simopoulou1, Vana Tsimourtou2, Christina Katsiari1, Marianna Vlychou3, Dimitrios P Bogdanos1, Lazaros I Sakkas1.   

Abstract

Reactivation of viruses occurs in autoimmune disorders in the setting of certain immunosuppressive drugs. We describe a 54-year-old female with systemic sclerosis and extensive cutaneous calcinosis who had been treated with methotrexate for 18 months and presented with headache and neurological deficits. She was diagnosed with progressive multifocal leukoencephalopathy, a rare disease caused by JC virus. Methotrexate was discontinued and mirtazapine plus mefloquine were added. The patient showed a slow recovery and five years later she had complete resolution of progressive multifocal leukoencephalopathy clinical manifestations. Calcinosis had a limited response to various agents and severely affected daily activities of the patient. This case report, highlights the importance of clinical suspicion for progressive multifocal leukoencephalopathy in every patient with immune-mediated disease, even on weak immunosuppressant, who presents with central nervous system manifestations and also the unmet therapeutic need for systemic sclerosis-associated calcinosis.
© The Author(s) 2020.

Entities:  

Keywords:  JC virus; Progressive multifocal leukoencephalopathy; calcinosis; methotrexate; systemic sclerosis

Year:  2020        PMID: 35382519      PMCID: PMC8922622          DOI: 10.1177/2397198320926883

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  43 in total

1.  Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients.

Authors:  J Collazos; J Mayo; E Martínez; M S Blanco
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Adaptation of Addenbrooke's Cognitive Examination-Revised for the Greek population.

Authors:  E Konstantinopoulou; M H Kosmidis; P Ioannidis; G Kiosseoglou; D Karacostas; N Taskos
Journal:  Eur J Neurol       Date:  2011-03       Impact factor: 6.089

Review 3.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

4.  Therapy: Targeted but not trouble-free: efalizumab and PML.

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2009-08       Impact factor: 20.543

Review 5.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

Review 6.  Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area.

Authors:  Dhanashri P Miskin; Igor J Koralnik
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

7.  Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy.

Authors:  Christian Wüthrich; Yi Min Cheng; Jeffrey T Joseph; Santosh Kesari; Curt Beckwith; Edward Stopa; Jeanne E Bell; Igor J Koralnik
Journal:  J Neuropathol Exp Neurol       Date:  2009-01       Impact factor: 3.685

8.  Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors.

Authors:  Adrian Egli; Laura Infanti; Alexis Dumoulin; Andreas Buser; Jacqueline Samaridis; Christine Stebler; Rainer Gosert; Hans H Hirsch
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

9.  Progressive multifocal leukoencephalopathy associated with infliximab.

Authors:  L Sammut; D Wallis; C Holroyd
Journal:  J R Coll Physicians Edinb       Date:  2016-09

Review 10.  The human JC polyomavirus (JCPyV): virological background and clinical implications.

Authors:  Hans H Hirsch; Piotr Kardas; Denise Kranz; Celine Leboeuf
Journal:  APMIS       Date:  2013-06-19       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.